ARSLON

ARSLON is a digital medical device software company developing ArslonHeart-CAD, a 12-lead ECG-based clinical decision support solution for coronary artery disease screening. The software analyzes routine ECG data through an AI-enabled process to provide information on coronary artery stenosis risk, estimated fractional flow reserve (eFFR) and the number of stenosed coronary vessels, supporting earlier identification of high-risk ischemic heart disease. Founded in 2025, ARSLON is developing the product through joint research with Seoul National University Hospital and has secured an LOI for product use from SNUH Main Campus. The company has also obtained a digital medical device manufacturing license and GMP certification.